Business
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., August 11, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the second quarter ended June 30, 2025.
About this update from Option Care Health, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/a64ab2bf3746c02f39c4d78c81bf70ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/snriODjAGckNhW_.mHHKpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a64ab2bf3746c02f39c4d78c81bf70ab","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/wRQ7MrnAODvXzWJLAGz_eQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a64ab2bf3746c02f39c4d78c81bf70ab","width":1121,"height":442}},"lazy":false},{"type":"text","content":"Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026","length":198,"tagName":"p","attribs":{}},{"type":"text","content":"Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S.","length":108,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., August 11, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development pipeline and reported financial results for the second quarter ended June 30, 2025.","length":373,"tagName":"p"},{"type":"text","content":"Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, "We achieved many critical milestones over the last quarter that significantly advance our research programs and strengthen our business model. Specifically, we completed enrollment in our pivotal Phase 3 NEAT clinical trial, secured additional financing to extend our operating runway sufficiently beyond topline results, and solidified our commercial development planning through our strategic partn...